Sulconazole

Summary

Sulconazole (CHEMBL1221) is an approved small molecule (ATC D01AC09).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D01AC09
• Chemistry: 397.7 Da · C18H15Cl3N2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1221
Name	Sulconazole
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5318
ChEBI	CHEBI:77776
ATC	D01AC09
Molecular formula	C18H15Cl3N2S
Molecular weight	397.7
InChIKey	AFNXATANNDIXLG-UHFFFAOYSA-N

SMILES: C1=CC(=CC=C1CSC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl

IUPAC name: 1-[2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole

ChEBI definition: A member of the class of imidazoles that is 1-ethyl-1H-imidazole in which one of the hydrogens of the methyl group is replaced by a (4-chlorobenzyl)sulfanediyl group while a second is replaced by a 2,4-dichlorophenyl group.

Also known as: Sulconazol, Sulconazole, sulconazole, SULCONAZOLE, SULCONAZOLE NITRATE

Parent form; salt/anhydrous children: CHEMBL1200348

Patent coverage: 3,344 distinct patent families (12,121 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 12,118 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 40 (assay-derived). Sample: Indoleamine 2,3-dioxygenase 1, Muscarinic acetylcholine receptor M4, 5-hydroxytryptamine receptor 2B, Thromboxane-A synthase, Tyrosine-protein kinase Fyn, Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Beta-lactamase, Glucocorticoid receptor.

Bioactivity

ChEMBL activities: 52 potent at pChembl ≥ 5 of 66 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP2C19	7.8	IC50	16	nM	CHEMBL_ACT_7803392
CYP3A4	7.16	IC50	70	nM	CHEMBL_ACT_7803400
SLC6A4	7.12	Ki	75	nM	CHEMBL_ACT_7805611
SLC6A4	6.85	IC50	141	nM	CHEMBL_ACT_7805610
TBXAS1	6.74	IC50	183	nM	CHEMBL_ACT_7805624
CYP2C9	6.7	IC50	200	nM	CHEMBL_ACT_7803394
SLC6A4	6.29	AC50	510	nM	CHEMBL_ACT_25150945
CHRM4	6.26	Ki	552	nM	CHEMBL_ACT_7803471
CYP1A2	6.22	IC50	600	nM	CHEMBL_ACT_7803388
ADRA2C	6.14	Ki	717	nM	CHEMBL_ACT_7801319
CHRM3	6.14	Ki	721	nM	CHEMBL_ACT_7803469
CYP2D6	6.1	IC50	800	nM	CHEMBL_ACT_7803396
CHRM1	6.05	Ki	885	nM	CHEMBL_ACT_7803465
DRD3	5.98	Ki	1054	nM	CHEMBL_ACT_7803407
HTR2A	5.95	Ki	1122	nM	CHEMBL_ACT_7805599
SLC6A3	5.86	Ki	1371	nM	CHEMBL_ACT_7803411
HTR2C	5.84	Ki	1459	nM	CHEMBL_ACT_7805603
ADORA3	5.83	Ki	1485	nM	CHEMBL_ACT_7801305
ADRA2A	5.82	Ki	1516	nM	CHEMBL_ACT_7801315
ADRA2B	5.79	Ki	1636	nM	CHEMBL_ACT_7801317
TACR2	5.78	Ki	1653	nM	CHEMBL_ACT_7805621
OPRK1	5.77	AC50	1700	nM	CHEMBL_ACT_25130004
SLC6A3	5.76	IC50	1726	nM	CHEMBL_ACT_7803410
CHRM5	5.73	Ki	1873	nM	CHEMBL_ACT_7803473
HTR2B	5.72	Ki	1922	nM	CHEMBL_ACT_7805601
SLC6A2	5.7	Ki	2010	nM	CHEMBL_ACT_7801327
SLC6A2	5.69	IC50	2027	nM	CHEMBL_ACT_7801326
KCNH2	5.62	AC50	2400	nM	CHEMBL_ACT_25118772
ADORA3	5.58	IC50	2628	nM	CHEMBL_ACT_7801304
CHRM5	5.58	IC50	2607	nM	CHEMBL_ACT_7803472

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).